AlphAIAlphAI — Financial news for AI agents
thestarphoenix.comAUG 172 min read$PROF

Profound’s Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days’

Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) announced the launch of new real-time interventional MRI software, its latest Treatment Delivery Consol (TDC). The company says the most recent TDC software could help customers reach up to 6 TULSA Procedures per system per day, outlining a roadmap toward full “TULSA Days.”

Original reporting
thestarphoenix.com
Published Aug 17, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 1:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$PROF
Bullish
medium confidence
Mentioned
$PROF
Relevance
5/10
AlphAI data visualization · based on thestarphoenix.com
Decision brief

The 30-second read

$PROFBullishLow
01

Why it matters

The announcement frames the latest TDC software as enabling higher daily procedure counts per system, which could improve customer economics if achievable in practice.

02

Market read

This is a product launch with an operational throughput roadmap, but the excerpt lacks financial guidance, customer adoption, or regulatory milestones.

03

What to watch

Traders may want to verify whether the software requires hardware upgrades, changes in clinical workflow, or regulatory/clinical validation beyond what is stated here.

Relevance 5/10Novelty 4/10Timing: today’s product announcement

Background

Profound is a commercial-stage interventional MRI (iMRI) medical device company; it announced a new Treatment Delivery Consol (TDC) software version.

Company-level read

Ticker impact

$PROFBullishMedium confidence
Context

Profound introduced new TDC software, positioning it as a roadmap to perform up to 6 TULSA Procedures per system per day.

Expected impact

Near-term impact likely limited unless follow-on coverage quantifies customer uptake, procedure volume, or reimbursement effects.

Evidence & confidence

This is a product introduction with operational claims (throughput) but no guidance, trial results, or contract wins disclosed in the provided text.

Market effects

Sector

Could modestly support sentiment around interventional MRI workflow software and procedure throughput improvements.

Regional

No clear regional read-through beyond North American medtech interest.

Global

Limited based on the provided text, which does not mention international rollouts or regulatory approvals.

Counterpoint

What could challenge this read

Throughput claims may not translate into real-world utilization, and without customer adoption data the market may discount the impact.

Key entities

  • company
    Profound Medical Corp.

    Commercial-stage iMRI device company introducing new TDC software for treatment delivery.

  • product
    Treatment Delivery Consol (TDC) software

    Profound’s iMRI treatment delivery software, positioned to support up to 6 TULSA Procedures per system per day.

  • procedure
    TULSA Procedures

    Profound’s interventional MRI procedure category referenced in the throughput claim.

Read at source← All news

Related articles

OCT 7
$PROFMed

Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg…

Profound Medical Corp. (PROF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (N

SEC EDGAR 8-K2 min
AUG 6
$PROFMed

Profound Medical Reports Second Quarter 2026 Financial Results

Profound Medical Corp. (PROF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Profound Medical Reports Second Quarter 2026 Financial Results – Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong clinical, c

SEC EDGAR 8-K6 min
OCT 7
$CAPRMedAI 8/10

Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears

Capricor presented two-year data on deramiocel, showing a 1.56-point difference in upper-limb decline for the delayed-start group. Patients treated for two years had a 3.4-point decline in PUL 2.0. Cardiac MRI data showed a 2.8% treatment effect on LVEF. The company plans to explore regulatory pathways outside the U.S. and monitor safety in combination therapies.

finance.yahoo.com2 min
OCT 7
$MPMed

MP Materials Expands Rare Earth Manufacturing in North Texas

MP Materials opened a magnet manufacturing plant in Fort Worth, employing 350+ workers, with plans to expand to 2,000. The facility supports contracts with General Motors and Apple, including a $500M deal with Apple. The company is also building a 1.2M sq ft campus in Northlake. These expansions aim to boost domestic rare earth magnet production and supply chain capacity.

constructionowners.com2 min
OCT 7
$MSFTHigh

Microsoft’s $665 target hinges on a new AI advantage

Melius Research upgraded Microsoft (MSFT) to Buy with a $665 price target, citing AI security and governance demand. Microsoft's Azure, Microsoft 365, and cybersecurity tools position it to manage AI agents, with Agent 365 extending controls to AI. Azure revenue grew 43% in Q4, and Microsoft's cloud backlog increased 84% to $678 billion. Melius forecasts Azure growth of over 50% by fiscal 2027, driven by AI infrastructure and management needs.

finance.yahoo.com3 min
OCT 7
$IONQMed

IonQ Advances to Stage C in DARPA Quantum Initiative, Shares Tra

IonQ Inc. (NYSE: IONQ) advanced to Stage C in DARPA's Quantum Benchmarking Initiative, securing a potential $300M agreement. The company's P/S ratio is 59.44, below its historical median of 138.4x. IonQ has a GF Score of 47/100, indicating mixed fundamentals. Insiders have sold more shares than they've bought in the past year, while institutional ownership remains steady.

gurufocus.com2 min